<p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）在周四更新了其 2025 财年的收益指引。该公司提供的每股收益（EPS）指引为 6.600-6.700，而市场共识预期为 6.610。该公司发布的收入指引为 4000 亿美元-4000 亿美元，而市场共识收入预期为 3990 亿美元。</p>
<h2>分析师设定新的目标价格</h2>
<ul>
<li>CVS Health 因收入增长而上涨，股息保持强劲</li>
</ul>
<p>CVS 最近成为几份研究报告的主题。摩根士丹利在 12 月 10 日的研究报告中将 CVS Health 的目标股价从 89.00 美元上调至 93.00 美元，并给予该股票 “超配” 评级。富国银行在 11 月 13 日的研究报告中将 CVS Health 的目标价格从 103.00 美元下调至 102.00 美元，并为该公司设定了 “超配” 评级。TD Cowen 在 12 月 10 日的研究报告中将 CVS Health 的目标价格从 100.00 美元上调至 105.00 美元，并给予该公司 “买入” 评级。雷蒙德·詹姆斯金融在 10 月 31 日的研究报告中将 CVS Health 的目标价格从 75.00 美元上调至 90.00 美元。最后，沃尔夫研究在 12 月 8 日的研究报告中将 CVS Health 的目标价格从 85.00 美元上调至 100.00 美元，并给予该公司 “跑赢大盘” 评级。两位股票研究分析师给予该股票 “强烈买入” 评级，二十位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat 的数据，CVS Health 的共识评级为 “适度买入”，共识目标价格为 94.67 美元。</p>
<p><strong>获取我们关于 CVS Health 的最新报告</strong></p>
<h2>CVS Health 股价下跌 0.4%</h2>
<ul>
<li>MarketBeat 周回顾 – 05/12 - 05/16</li>
</ul>
<p>周四，CVS 股票开盘价为 77.95 美元。CVS Health 的 1 年最低价为 43.56 美元，1 年最高价为 85.15 美元。该公司的债务与股本比率为 0.83，流动比率为 0.83，速动比率为 0.63。该公司的 50 日移动平均价格为 79.08 美元，200 日移动平均价格为 72.24 美元。该公司的市值为 989.5 亿美元，市盈率为 205.14，市盈增长比率为 0.77，贝塔值为 0.48。</p>
<p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）在 10 月 29 日的季度财报中宣布了其季度收益结果。该药房运营商报告的每股收益（EPS）为 1.60 美元，超出分析师的共识预期 1.36 美元，超出幅度为 0.24 美元。该公司在本季度的收入为 1028.7 亿美元，而市场共识预期为 988.5 亿美元。CVS Health 的净利润率为 0.12%，股本回报率为 11.45%。该公司的收入较去年同期增长了 7.8%。去年同期，该公司每股收益为 1.09 美元。CVS Health 已将其 2025 财年的指引设定为 6.550-6.650 EPS。作为一个整体，卖方分析师预测 CVS Health 在当前财年将发布 5.89 EPS。</p>
<h2>对 CVS Health 的对冲基金看法</h2>
<ul>
<li>现在是买入 Novo Nordisk 股票的时机吗？</li>
</ul>
<p>几家对冲基金和其他机构投资者最近买入和卖出了该公司的股票。道富银行在第三季度将其在 CVS Health 的持股增加了 0.3%。道富银行目前拥有 58,938,286 股该药房运营商的股票，价值 4,443,357,000 美元，此前在上个季度购买了 149,701 股。Ameriprise Financial Inc.在第二季度将其在 CVS Health 的持股增加了 5.2%。Ameriprise Financial Inc.目前拥有 7,855,845 股该药房运营商的股票，价值 541,903,000 美元，此前在上个季度购买了 385,806 股。阿穆迪在第三季度将其在 CVS Health 的持股增加了 95.3%。阿穆迪目前拥有 7,453,980 股该药房运营商的股票，价值 572,665,000 美元，此前在上个季度购买了 3,637,943 股。威灵顿管理集团在第三季度将其在 CVS Health 的持股增加了 391.6%。威灵顿管理集团目前拥有 6,330,717 股该药房运营商的股票，价值 477,273,000 美元，此前在上个季度购买了 5,042,816 股。最后，雷蒙德·詹姆斯金融在第二季度将其在 CVS Health 的持股增加了 4.4%。雷蒙德·詹姆斯金融目前拥有 3,191,584 股该药房运营商的股票，价值 220,155,000 美元，此前在上个季度购买了 133,875 股。80.66% 的股票由机构投资者和对冲基金持有。</p>
<h2>CVS Health 公司简介</h2>
<p>（获取免费报告）</p>
<p>CVS Health Corporation 在美国提供健康解决方案。它通过医疗保险、健康服务和药房及消费者健康部门运营。医疗保险部门提供传统、自愿和消费者导向的健康保险产品及相关服务。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 CVS Health</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>降息使这三只收入 ETF 比以往更具吸引力</li>
<li>内部人士卖出解释：这能否影响你的投资选择？</li>
<li>在上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 CVS Health 吗？</h2>
<p>在考虑 CVS Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 CVS Health 并不在名单上。</p>
<p>虽然 CVS Health 目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西维斯

<p>CVS Health 更新了其 2025 财年的收益指引，预计每股收益（EPS）为 6.600-6.700，高于市场共识预期的 6.610，收入指引为 4000 亿美元，超过市场共识的 3990 亿美元。分析师们已调整了他们的目标价，市场共识评级为 “适度买入”，目标价为 94.67 美元。CVS Health 最近的季度收益超出预期，净利润率为 0.12%，股本回报率为 11.45%。机构投资者已增加了对该公司的持股</p>

<p>CVS Health (NYSE:CVS - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.600-6.700 for the period, compared to the consensus estimate of 6.610. The company issued revenue guidance of $400.0 billion-$400.0 billion, compared to the consensus revenue estimate of $399.0 billion.</p>
<div class="lb-trans"><p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）在周四更新了其 2025 财年的收益指引。该公司提供的每股收益（EPS）指引为 6.600-6.700，而市场共识预期为 6.610。该公司发布的收入指引为 4000 亿美元-4000 亿美元，而市场共识收入预期为 3990 亿美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的目标价格</h2>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>CVS Health 因收入增长而上涨，股息保持强劲</li>
</ul>
</div><p>CVS has been the subject of several recent research reports. Morgan Stanley increased their target price on shares of CVS Health from $89.00 to $93.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. Wells Fargo &amp; Company decreased their price objective on CVS Health from $103.00 to $102.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, November 13th. TD Cowen lifted their target price on CVS Health from $100.00 to $105.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, December 10th. Raymond James Financial upped their price target on CVS Health from $75.00 to $90.00 in a research note on Friday, October 31st. Finally, Wolfe Research lifted their price objective on shares of CVS Health from $85.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, CVS Health has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $94.67.</p>
<div class="lb-trans"><p>CVS 最近成为几份研究报告的主题。摩根士丹利在 12 月 10 日的研究报告中将 CVS Health 的目标股价从 89.00 美元上调至 93.00 美元，并给予该股票 “超配” 评级。富国银行在 11 月 13 日的研究报告中将 CVS Health 的目标价格从 103.00 美元下调至 102.00 美元，并为该公司设定了 “超配” 评级。TD Cowen 在 12 月 10 日的研究报告中将 CVS Health 的目标价格从 100.00 美元上调至 105.00 美元，并给予该公司 “买入” 评级。雷蒙德·詹姆斯金融在 10 月 31 日的研究报告中将 CVS Health 的目标价格从 75.00 美元上调至 90.00 美元。最后，沃尔夫研究在 12 月 8 日的研究报告中将 CVS Health 的目标价格从 85.00 美元上调至 100.00 美元，并给予该公司 “跑赢大盘” 评级。两位股票研究分析师给予该股票 “强烈买入” 评级，二十位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat 的数据，CVS Health 的共识评级为 “适度买入”，共识目标价格为 94.67 美元。</p>
</div><p><strong>Get Our Latest Report on CVS Health</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 CVS Health 的最新报告</strong></p>
</div><h2>CVS Health Trading Down 0.4%</h2>
<div class="lb-trans"><h2>CVS Health 股价下跌 0.4%</h2>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 05/12 - 05/16</li>
</ul>
</div><p>Shares of CVS stock opened at $77.95 on Thursday. CVS Health has a 1-year low of $43.56 and a 1-year high of $85.15. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. The business's fifty day moving average price is $79.08 and its 200 day moving average price is $72.24. The firm has a market capitalization of $98.95 billion, a PE ratio of 205.14, a P/E/G ratio of 0.77 and a beta of 0.48.</p>
<div class="lb-trans"><p>周四，CVS 股票开盘价为 77.95 美元。CVS Health 的 1 年最低价为 43.56 美元，1 年最高价为 85.15 美元。该公司的债务与股本比率为 0.83，流动比率为 0.83，速动比率为 0.63。该公司的 50 日移动平均价格为 79.08 美元，200 日移动平均价格为 72.24 美元。该公司的市值为 989.5 亿美元，市盈率为 205.14，市盈增长比率为 0.77，贝塔值为 0.48。</p>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.24. The business had revenue of $102.87 billion during the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business's revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. As a group, sell-side analysts forecast that CVS Health will post 5.89 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）在 10 月 29 日的季度财报中宣布了其季度收益结果。该药房运营商报告的每股收益（EPS）为 1.60 美元，超出分析师的共识预期 1.36 美元，超出幅度为 0.24 美元。该公司在本季度的收入为 1028.7 亿美元，而市场共识预期为 988.5 亿美元。CVS Health 的净利润率为 0.12%，股本回报率为 11.45%。该公司的收入较去年同期增长了 7.8%。去年同期，该公司每股收益为 1.09 美元。CVS Health 已将其 2025 财年的指引设定为 6.550-6.650 EPS。作为一个整体，卖方分析师预测 CVS Health 在当前财年将发布 5.89 EPS。</p>
</div><h2>Hedge Funds Weigh In On CVS Health</h2>
<div class="lb-trans"><h2>对 CVS Health 的对冲基金看法</h2>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>现在是买入 Novo Nordisk 股票的时机吗？</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp grew its holdings in CVS Health by 0.3% in the third quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator's stock valued at $4,443,357,000 after purchasing an additional 149,701 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of CVS Health by 5.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 7,855,845 shares of the pharmacy operator's stock worth $541,903,000 after buying an additional 385,806 shares during the last quarter. Amundi boosted its position in shares of CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator's stock worth $572,665,000 after buying an additional 3,637,943 shares in the last quarter. Wellington Management Group LLP grew its stake in CVS Health by 391.6% in the 3rd quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator's stock valued at $477,273,000 after acquiring an additional 5,042,816 shares during the last quarter. Finally, Raymond James Financial Inc. increased its holdings in CVS Health by 4.4% during the 2nd quarter. Raymond James Financial Inc. now owns 3,191,584 shares of the pharmacy operator's stock valued at $220,155,000 after acquiring an additional 133,875 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买入和卖出了该公司的股票。道富银行在第三季度将其在 CVS Health 的持股增加了 0.3%。道富银行目前拥有 58,938,286 股该药房运营商的股票，价值 4,443,357,000 美元，此前在上个季度购买了 149,701 股。Ameriprise Financial Inc.在第二季度将其在 CVS Health 的持股增加了 5.2%。Ameriprise Financial Inc.目前拥有 7,855,845 股该药房运营商的股票，价值 541,903,000 美元，此前在上个季度购买了 385,806 股。阿穆迪在第三季度将其在 CVS Health 的持股增加了 95.3%。阿穆迪目前拥有 7,453,980 股该药房运营商的股票，价值 572,665,000 美元，此前在上个季度购买了 3,637,943 股。威灵顿管理集团在第三季度将其在 CVS Health 的持股增加了 391.6%。威灵顿管理集团目前拥有 6,330,717 股该药房运营商的股票，价值 477,273,000 美元，此前在上个季度购买了 5,042,816 股。最后，雷蒙德·詹姆斯金融在第二季度将其在 CVS Health 的持股增加了 4.4%。雷蒙德·詹姆斯金融目前拥有 3,191,584 股该药房运营商的股票，价值 220,155,000 美元，此前在上个季度购买了 133,875 股。80.66% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>CVS Health Company Profile</h2>
<div class="lb-trans"><h2>CVS Health 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p>
<div class="lb-trans"><p>CVS Health Corporation 在美国提供健康解决方案。它通过医疗保险、健康服务和药房及消费者健康部门运营。医疗保险部门提供传统、自愿和消费者导向的健康保险产品及相关服务。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>What is MarketRank™? How to Use it</li>
<li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 CVS Health</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>降息使这三只收入 ETF 比以往更具吸引力</li>
<li>内部人士卖出解释：这能否影响你的投资选择？</li>
<li>在上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 CVS Health 吗？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CVS Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 CVS Health 并不在名单上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CVS Health 目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CVS Health（纽约证券交易所代码：CVS）发布 2025 财年收益指引